GlassScriptPhysician profile
Shari Evalynn Rozen
NPI 1356393987
$3,487.63
in general payments reported to CMS, 2019-2025
24 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.20 · 2020: $161 · 2021: $536 · 2022: $612 · 2023: $1,051 · 2024: $703 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,735.16 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $489.88 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $280.61 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $179.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.53 | 2021-2024 | |
| Allergan, INC. | $136.60 | 2019-2020 | |
| Abbott Laboratories | $86.04 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $72.41 | 2020-2023 | Aimovig |
| Lilly USA, LLC | $60.76 | 2023-2024 | Mounjaro, Zepbound |
| Upsher-Smith Laboratories LLC | $47.03 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $42.07 | 2023-2024 | Ajovy |
| Edwards Lifesciences Corporation | $33.20 | 2024 | |
| Ucb, INC. | $23.70 | 2024 | Nayzilam |
| Novartis Pharmaceuticals Corporation | $23.49 | 2019 | |
| Lundbeck LLC | $23.42 | 2025 | Vyepti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.28 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Rozen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.